Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report
This report describes vedolizumab’s clinical efficacy and safety in a patient with severe ulcerative colitis on haemodialysis for an end-stage kidney failure. The patient was a 75-year-old man on long-standing chronic diffusive three times per week haemodialytic treatment due to vascular nephropathy...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2023-04-01
|
| Series: | SAGE Open Medical Case Reports |
| Online Access: | https://doi.org/10.1177/2050313X231165641 |
| _version_ | 1797848910442528768 |
|---|---|
| author | Guglielmo Albertini Petroni Laura Francesca Pisani Edoardo Borsotti Maria Doria Maria Laura Annunziata |
| author_facet | Guglielmo Albertini Petroni Laura Francesca Pisani Edoardo Borsotti Maria Doria Maria Laura Annunziata |
| author_sort | Guglielmo Albertini Petroni |
| collection | DOAJ |
| description | This report describes vedolizumab’s clinical efficacy and safety in a patient with severe ulcerative colitis on haemodialysis for an end-stage kidney failure. The patient was a 75-year-old man on long-standing chronic diffusive three times per week haemodialytic treatment due to vascular nephropathy. At the presentation, the patient had severe bloody diarrhoea treated with a steroid cycle with temporary benefits and then developed steroid dependence. Upon remission, the patient started vedolizumab (Entivyo ® ) as maintenance therapy. After 6 weeks of induction, patient started the maintenance therapy with an infusion every 8 weeks. After the sixth infusion, the interval was prolonged to 9 weeks because of the good and fast response. Vedolizumab treatment proceeded without adverse events. However, no changes in renal function were noted during the same period, no complications were reported, and the patient regularly continued haemodialysis. At the second induction infusion (week 2) and the second maintenance infusion (week 22), we measured vedolizumab serum level before and after haemodialysis, observing no significant changes. Our case is the first report about using vedolizumab in a patient under haemodialysis, showing that vedolizumab can be safe, well tolerated, and effective in patients undergoing haemodialysis. However, more extensive trials are needed to prove its use in these patients. |
| first_indexed | 2024-04-09T18:36:21Z |
| format | Article |
| id | doaj.art-7304c58ed821476c923b1a7395e374d6 |
| institution | Directory Open Access Journal |
| issn | 2050-313X |
| language | English |
| last_indexed | 2024-04-09T18:36:21Z |
| publishDate | 2023-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | SAGE Open Medical Case Reports |
| spelling | doaj.art-7304c58ed821476c923b1a7395e374d62023-04-11T10:33:54ZengSAGE PublishingSAGE Open Medical Case Reports2050-313X2023-04-011110.1177/2050313X231165641Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case reportGuglielmo Albertini Petroni0Laura Francesca Pisani1Edoardo Borsotti2Maria Doria3Maria Laura Annunziata4Postgraduate School in Gastroenterology, University of Milan, Milan, ItalyGastroenterology and Endoscopy Unit, IRCCS Policlinico San Donato, San Donato Milanese, ItalyGastroenterology and Endoscopy Unit, IRCCS Policlinico San Donato, San Donato Milanese, ItalyNephrology and Dialysis Unit, IRCCS Policlinico San Donato, San Donato Milanese, ItalyGastroenterology and Endoscopy Unit, IRCCS Policlinico San Donato, San Donato Milanese, ItalyThis report describes vedolizumab’s clinical efficacy and safety in a patient with severe ulcerative colitis on haemodialysis for an end-stage kidney failure. The patient was a 75-year-old man on long-standing chronic diffusive three times per week haemodialytic treatment due to vascular nephropathy. At the presentation, the patient had severe bloody diarrhoea treated with a steroid cycle with temporary benefits and then developed steroid dependence. Upon remission, the patient started vedolizumab (Entivyo ® ) as maintenance therapy. After 6 weeks of induction, patient started the maintenance therapy with an infusion every 8 weeks. After the sixth infusion, the interval was prolonged to 9 weeks because of the good and fast response. Vedolizumab treatment proceeded without adverse events. However, no changes in renal function were noted during the same period, no complications were reported, and the patient regularly continued haemodialysis. At the second induction infusion (week 2) and the second maintenance infusion (week 22), we measured vedolizumab serum level before and after haemodialysis, observing no significant changes. Our case is the first report about using vedolizumab in a patient under haemodialysis, showing that vedolizumab can be safe, well tolerated, and effective in patients undergoing haemodialysis. However, more extensive trials are needed to prove its use in these patients.https://doi.org/10.1177/2050313X231165641 |
| spellingShingle | Guglielmo Albertini Petroni Laura Francesca Pisani Edoardo Borsotti Maria Doria Maria Laura Annunziata Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report SAGE Open Medical Case Reports |
| title | Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report |
| title_full | Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report |
| title_fullStr | Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report |
| title_full_unstemmed | Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report |
| title_short | Efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end-stage kidney failure: A case report |
| title_sort | efficacy of vedolizumab as maintenance therapy in a patient with ulcerative colitis receiving haemodialysis in end stage kidney failure a case report |
| url | https://doi.org/10.1177/2050313X231165641 |
| work_keys_str_mv | AT guglielmoalbertinipetroni efficacyofvedolizumabasmaintenancetherapyinapatientwithulcerativecolitisreceivinghaemodialysisinendstagekidneyfailureacasereport AT laurafrancescapisani efficacyofvedolizumabasmaintenancetherapyinapatientwithulcerativecolitisreceivinghaemodialysisinendstagekidneyfailureacasereport AT edoardoborsotti efficacyofvedolizumabasmaintenancetherapyinapatientwithulcerativecolitisreceivinghaemodialysisinendstagekidneyfailureacasereport AT mariadoria efficacyofvedolizumabasmaintenancetherapyinapatientwithulcerativecolitisreceivinghaemodialysisinendstagekidneyfailureacasereport AT marialauraannunziata efficacyofvedolizumabasmaintenancetherapyinapatientwithulcerativecolitisreceivinghaemodialysisinendstagekidneyfailureacasereport |